BS_QXKRN6CR
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 55.92
- os_event
- false
- age_years
- 12.381
- sex
- F
- race
- White
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.66604934
- umap2_2d
- 1.622782192
- umap1_3d
- -0.12508501
- umap2_3d
- 3.890399504
- umap3_3d
- -3.191302425
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- MYC_TARGETS_V1+0.510
- PROTEIN_SECRETION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.490
- G2M_CHECKPOINT+0.430
- DNA_REPAIR+0.370
- ADIPOGENESIS+0.270
- MTORC1_SIGNALING+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.270
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.430
- KRAS_SIGNALING_DN-0.420
- APICAL_SURFACE-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- MYOGENESIS-0.400
- COAGULATION-0.390
- IL6_JAK_STAT3_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.380
- HYPOXIA-0.370
- APICAL_JUNCTION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QXKRN6CR | Supratentorial Ependymoma | — | 0.983 |
| 2 | BS_7G42J2SK | Supratentorial Ependymoma | — | 0.944 |
| 3 | SJEPD030854_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.935 |
| 4 | BS_FTKPQ5FZ | Supratentorial Ependymoma | — | 0.928 |
| 5 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.907 |
| 6 | MDT-AP-3088 | Med | Medulloblastoma | 0.899 |
| 7 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.898 |
| 8 | SJEPD030743_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.895 |
| 9 | MNG33 | — | — | 0.895 |
| 10 | BS_7G42J2SK | EPN | Supratentorial EPN | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |